STAMFORD, Conn., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that new preclinical data for the company's LOXO-292 and LOXO-195 programs will be presented at the 28 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 - December 2, 2016 in Munich, Germany. The details of the poster presentations are as follows: LOXO-292Date: December 1, 2016 Title: The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers Session: Molecular targeted agents II AbstractCode: 441 PosterNumber: 120 Location: Exhibition Hall LOXO-195Date: December 1, 2016 Title: The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers Session: Molecular targeted agents II AbstractCode: 442 PosterNumber: 121 Location: Exhibition Hall About Loxo OncologyLoxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.